Compare Stocks

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$140.89 -0.9%	$149.20	$66.03 ▼ $161.00	$8.20B	0.5	374,777 shs	222,167 shs
ESK Eskay Mining	C$0.38 -1.3%	C$0.34	C$0.26 ▼ C$1.33	C$68.86M	1.55	67,755 shs	14,000 shs
LLG Mason Resources	C$0.13 -3.8%	C$0.14	C$0.12 ▼ C$0.33	C$17.66M	1.83	83,450 shs	3,016 shs
RCK Rock Tech Lithium	C$1.18 +4.4%	C$1.18	C$0.95 ▼ C$2.55	C$119.48M	1.75	48,965 shs	66,205 shs
RPX Columbia Growth Equity Strategy Fund	$40.84	$0.00	$39.00 ▼ $48.97	N/A	N/A	2,117 shs	N/A

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+0.47%	-6.82%	-3.33%	+6.91%	+74.91%
ESK Eskay Mining	+7.04%	+4.11%	+10.14%	+24.59%	-48.65%
LLG Mason Resources	0.00%	+8.33%	-7.14%	-36.59%	-56.67%
RCK Rock Tech Lithium	-2.59%	-1.74%	-8.13%	-9.60%	-55.69%
RPX Columbia Growth Equity Strategy Fund	0.00%	0.00%	0.00%	0.00%	0.00%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	1.5751 of 5 stars	3.4	1.0	0.0	0.0	2.7	1.7	0.6
ESK Eskay Mining	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LLG Mason Resources	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCK Rock Tech Lithium	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPX Columbia Growth Equity Strategy Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	2.88	Moderate Buy	$173.25	22.97% Upside
ESK Eskay Mining	N/A	N/A	N/A	N/A
LLG Mason Resources	N/A	N/A	N/A	N/A
RCK Rock Tech Lithium	3.00	Buy	C$2.70	128.81% Upside
RPX Columbia Growth Equity Strategy Fund	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ESK, ASND, RPX, RCK, and LLG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$173.00
4/2/2024	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$165.00 ➝ $167.00
4/1/2024	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$173.00
3/15/2024	ASND Ascendis Pharma A/S	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$196.00 ➝ $260.00
2/8/2024	ASND Ascendis Pharma A/S	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$146.00 ➝ $182.00
2/8/2024	ASND Ascendis Pharma A/S	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$207.00 ➝ $225.00
2/6/2024	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$152.00 ➝ $173.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$288.08M	28.47	N/A	N/A	($2.73) per share	-51.61
ESK Eskay Mining	N/A	N/A	C$0.02 per share	17.32	C$0.04 per share	N/A
LLG Mason Resources	N/A	N/A	C$0.05 per share	2.75	C$0.15 per share	N/A
RCK Rock Tech Lithium	N/A	N/A	C$0.20 per share	5.85	C$0.41 per share	N/A
RPX Columbia Growth Equity Strategy Fund	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$521.07M	-$9.25	N/A	N/A	N/A	-180.61%	-16,574.15%	-55.10%	4/25/2024 (Estimated)
ESK Eskay Mining	-C$1.71M	N/A	N/A	∞	N/A	N/A	-22.33%	-18.06%	N/A
LLG Mason Resources	-C$3.93M	-C$0.03	N/A	∞	N/A	N/A	-15.69%	-7.63%	6/4/2024 (Estimated)
RCK Rock Tech Lithium	-C$36.74M	-C$0.38	N/A	∞	N/A	N/A	-75.83%	-41.19%	5/24/2024 (Estimated)
RPX Columbia Growth Equity Strategy Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ESK, ASND, RPX, RCK, and LLG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/28/2024	Q2 2024	LLG Mason Resources	N/A	-C$0.01	-C$0.01	C$0.01	N/A	N/A
2/7/2024	Q4 2023	ASND Ascendis Pharma A/S	-$2.15	-$1.66	+$0.49	-$1.66	$97.02 million	$148.62 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
ESK Eskay Mining	N/A	N/A	N/A	N/A	N/A
LLG Mason Resources	N/A	N/A	N/A	N/A	N/A
RCK Rock Tech Lithium	N/A	N/A	N/A	N/A	N/A
RPX Columbia Growth Equity Strategy Fund	$0.10	0.24%	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	3.56	2.50
ESK Eskay Mining	47.69	30.90	1.73
LLG Mason Resources	4.33	29.35	47.86
RCK Rock Tech Lithium	1.99	3.54	4.68
RPX Columbia Growth Equity Strategy Fund	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
ESK Eskay Mining	17.67%
LLG Mason Resources	24.78%
RCK Rock Tech Lithium	0.79%
RPX Columbia Growth Equity Strategy Fund	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
ESK Eskay Mining	16.98%
LLG Mason Resources	14.36%
RCK Rock Tech Lithium	8.45%
RPX Columbia Growth Equity Strategy Fund	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	879	58.22 million	34.93 million	Optionable
ESK Eskay Mining	N/A	183.62 million	N/A	Not Optionable
LLG Mason Resources	N/A	141.29 million	N/A	Not Optionable
RCK Rock Tech Lithium	N/A	101.25 million	N/A	Not Optionable
RPX Columbia Growth Equity Strategy Fund	N/A	N/A	N/A	Not Optionable

ESK, ASND, RPX, RCK, and LLG Headlines

Source	Headline
	Columbia Acorn C LIACX morningstar.com - April 13 at 10:21 PM
	IBM Plucks New Legal Chief From Mutual Fund Giant law.com - April 11 at 5:21 PM
	Axis ESG Integration Strategy Fund Direct Growth livemint.com - April 10 at 4:18 PM
	Commonfund wraps up its fourth secondaries fund at $1.1bn opalesque.com - April 3 at 3:57 PM
	Canara Robeco Equity Hybrid Fund Growth livemint.com - March 31 at 11:34 PM
	Compare with Columbia Disciplined Value Fund;I (CVQZX) msn.com - March 30 at 12:46 AM
	Calpers’ Latest Private-Equity Overhaul Stresses Tech, Growth Deals wsj.com - March 22 at 9:47 AM
	Columbia Dividend Income Adv morningstar.com - March 14 at 4:26 PM
	RiverPark Floating Rate CMBS Fund Q4 2023 Investor Letter seekingalpha.com - February 29 at 9:33 AM
	Graphic Packaging: Recent Capex Investments Suggest Substantial Free Cash Flow Growth Ahead seekingalpha.com - February 28 at 8:21 AM
	Columbia Dividend Income Inst morningstar.com - February 27 at 8:26 PM
	Columbia Select Large Cap Growth Fund;I wsj.com - February 21 at 3:58 PM
	Kotak Emerging Equity Scheme Growth livemint.com - February 21 at 3:58 PM
	HSBC Tax Saver Equity Fund Growth livemint.com - February 14 at 12:46 AM
	Axis Equity Saver Fund Direct Plan Growth livemint.com - February 1 at 8:04 PM
	Baron International Growth Fund Q4 2023 Shareholder Letter seekingalpha.com - January 28 at 8:56 PM
	PDX: Not The Credit Fund We Had Wished For (Rating Downgrade) seekingalpha.com - January 26 at 11:50 PM
	ClearBridge Mid Cap Growth Strategy Q4 2023 Portfolio Manager Commentary seekingalpha.com - January 20 at 12:12 PM
	Polaris Global Equity Composite Q4 2023 Commentary seekingalpha.com - January 18 at 12:43 PM
	Local fund manager beats stock market, peers 16 years in a row bizjournals.com - January 18 at 7:42 AM
	Blackstone’s First Private Equity Fund for Garden-Variety Millionaires Scores $1.3 Billion msn.com - January 9 at 1:18 PM
	NewSpring's Fourth Growth Equity Healthcare Fund Exceeds Its Target, Raising over $180 Million markets.businessinsider.com - January 2 at 2:05 PM
	How Charlotte private equity firms are approaching deals amid M&A slowdown bizjournals.com - November 13 at 5:01 PM
	ICICI Prudential Long Term Equity Fund (Tax Saving) Growth businesstoday.in - November 11 at 11:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024 6:10 AM
View Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

All Headlines

Company Descriptions

Ascendis Pharma A/S

NASDAQ:ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Eskay Mining

CVE:ESK

Eskay Mining Corp., a natural resource company, engages in the acquisition and exploration of mineral properties, and precious and base metal deposits in British Columbia, Canada. It holds 100% interests in the ESKAY-Corey property located in northwestern British Columbia. The company was formerly known as Kenrich-Eskay Mining Corp. and changed its name to Eskay Mining Corp. in November 2009. The company was founded in 1980 and is headquartered in Toronto, Canada.

Mason Resources

CVE:LLG

Mason Resources Inc., a mining and processing company, engages in the extraction, processing, and development of graphite deposits in Canada. The company primarily owns a 100% interest in the Lac Guéret graphite property located in Quebec, Canada. It also focuses on the production and commercialization of patented graphene products for various industrial sectors, including concrete, polymers, Li-ion batteries, and others; and development of value-added graphite products. The company was formerly known as Mason Graphite Inc. and changed its name to Mason Resources Inc. in October 2023. Mason Resources Inc. was incorporated in 2011 and is based in Laval, Canada.

Rock Tech Lithium

CVE:RCK

Rock Tech Lithium Inc. engages in the exploration and development of lithium properties. It holds a 100% interest in the Georgia Lake lithium project comprising 277 claim units and 41 mining leases located in the Thunder Bay Mining District of Ontario. The company focuses on developing and optimizing battery grade lithium hydroxide monohydrate. The company was formerly known as Rock Tech Resources Inc. and changed its name to Rock Tech Lithium Inc. in April 2010. Rock Tech Lithium Inc. was incorporated in 2010 and is headquartered in Toronto, Canada.

Columbia Growth Equity Strategy Fund

NYSEARCA:RPX

Columbia Large Cap Growth ETF, formerly Columbia Growth Equity Strategy Fund, seeks long-term capital appreciation by investing at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in equity securities of companies. The Fund may invest in companies of any market capitalization and in any industry. It expects to invest primarily in the securities of United States companies, and may also invest in United States securities tied economically to foreign investments, such as American Depositary Receipts. It invests in various sectors, such as information technology, industrials, healthcare, energy, financials, consumer staples, financials, materials and consumer discretionary. Columbia Management Investment Advisers, LLC serves as the manager of the Fund.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial